Quantitative rapid steady state T1 magnetic resonance imaging for cerebral blood volume mapping in mice: Lengthened measurement time window with intraperitoneal Gd-DOTA injection

Authors

  • Adriana T. Perles-Barbacaru,

    Corresponding author
    1. Université Joseph Fourier, Grenoble Institut des Neurosciences, F-38042, Grenoble, France
    2. Institut National de la Santé et de la Recherche Médicale (INSERM), U836, F-38042, Grenoble, France
    • Institut National de la Santé et de la Recherche Médicale (INSERM), U836, Grenoble Institut des Neurosciences, Bâtiment Edmond J. Safra, Chemin Fortuné Ferrini, F-38700 La Tronche – France
    Search for more papers by this author
  • François Berger,

    1. Université Joseph Fourier, Grenoble Institut des Neurosciences, F-38042, Grenoble, France
    2. Institut National de la Santé et de la Recherche Médicale (INSERM), U836, F-38042, Grenoble, France
    Search for more papers by this author
  • Hana Lahrech

    1. Université Joseph Fourier, Grenoble Institut des Neurosciences, F-38042, Grenoble, France
    2. Institut National de la Santé et de la Recherche Médicale (INSERM), U836, F-38042, Grenoble, France
    Search for more papers by this author

Abstract

This work demonstrates how the rapid steady state T1 MRI technique for cerebral blood volume fraction (BVf) quantification can be used with intraperitoneal Gd-DOTA injections in mice at 4.7 T. The peak signal amplitude after intravenous administration (0.7 mmol/kg) and the steady state signal amplitude reached 15 min after intraperitoneal administration (6 mmol/kg) in the same mice lead to equivalent BVf measures in the order of 0.02 in the brain. The resulting time window for BVf quantification is ≈30 min and allows for cerebral BVf mapping with increased spatial resolution or signal-to-noise ratio, or for monitoring functional BVf changes. A cerebral BVf increase of up to 25% induced by the vasodilator acetazolamide was observed, validating the vascular origin of the signal. The noninvasive and quantitative rapid steady state T1 technique can be used in serial studies to evaluate new drugs or disease models, such as antiangiogenic therapies in tumors. Magn Reson Med, 2013. © 2012 Wiley Periodicals, Inc.

Ancillary